Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2R01 for prevention of cardiac surgery-associated acute kidney injury
2025-523037-25-00Phase 2Authorised
- Sponsor
- River 2 Renal Corp
- Start
- Mar 2026
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) comparing R2R01 with Placebo (2 arms). Primary endpoints: Proportion of subjects developing acute kidney injury within 7 days and Treatment-emergent adverse events. Planned start Mar 2026; status: authorised.
02
Drugs
R2R01
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2025-523037-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523037-25-00.